Should I buy or sell Werewolf Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOWL shares. View HOWL analyst ratings or view top-rated stocks .

What is Werewolf Therapeutics' stock price target for 2024?

2 brokerages have issued 12-month target prices for Werewolf Therapeutics' shares. Their HOWL share price targets range from $9.00 to $15.00. On average, they predict the company's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 94.9% from the stock's current price. View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts .

How have HOWL shares performed in 2024?

Werewolf Therapeutics' stock was trading at $3.86 at the beginning of 2024. Since then, HOWL shares have increased by 52.8% and is now trading at $5.90. View the best growth stocks for 2024 here .

Are investors shorting Werewolf Therapeutics?

Werewolf Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 472,000 shares, an increase of 9.3% from the March 15th total of 432,000 shares. Based on an average trading volume of 240,200 shares, the short-interest ratio is currently 2.0 days. Currently, 1.6% of the shares of the stock are sold short. View Werewolf Therapeutics' Short Interest .

When is Werewolf Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HOWL earnings forecast .

How were Werewolf Therapeutics' earnings last quarter?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings results on Thursday, March, 7th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.10. The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.75 million. Werewolf Therapeutics had a negative trailing twelve-month return on equity of 32.25% and a negative net margin of 187.37%.

When did Werewolf Therapeutics IPO?

Werewolf Therapeutics (HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Werewolf Therapeutics' major shareholders?

Werewolf Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Denali Advisors LLC (0.06%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard . View institutional ownership trends .

How do I buy shares of Werewolf Therapeutics?

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HOWL

Werewolf Therapeutics (HOWL) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free HOWL Stock Alerts

$5.90

+0.03 (+0.51%)

(As of 04/19/2024 ET)

Compare

Today's Range: $5.62
▼
$5.98
50-Day Range: $4.69
▼
$7.91
52-Week Range: $1.57
▼
$8.19

Volume: 120,925 shs
Average Volume: 244,616 shs
Market Capitalization: $255.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.50

Get Werewolf Therapeutics alerts:

Werewolf Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 94.9% Upside
$11.50 Price Target
Short Interest: Healthy
1.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.33
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.38) to ($1.60) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.78 out of 5 stars

Medical Sector

446th out of 911 stocks

Pharmaceutical Preparations Industry

198th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Werewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Werewolf Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.61% of the float of Werewolf Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Werewolf Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Werewolf Therapeutics has recently increased by 9.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Werewolf Therapeutics does not currently pay a dividend.
Dividend Growth
Werewolf Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HOWL.

3.5

News and Social Media Coverage

News Sentiment
Werewolf Therapeutics has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Werewolf Therapeutics this week, compared to 1 article on an average week.
Search Interest
8 people have searched for HOWL on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
26.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.38) to ($1.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Werewolf Therapeutics is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Werewolf Therapeutics is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Werewolf Therapeutics has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Werewolf Therapeutics Stock (NASDAQ:HOWL)

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

HOWL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HOWL Stock News Headlines

April 19, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline Potential

April 12, 2024 | msn.com

Why Howl's turn-based tactics are ideal for mobile

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 5, 2024 | globenewswire.com

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

April 4, 2024 | seekingalpha.com

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

April 4, 2024 | globenewswire.com

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

March 15, 2024 | morningstar.com

Werewolf Therapeutics Inc HOWL

March 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Werewolf Therapeutics with Anticipated Surge on WTX-124 Phase 1 Data Release

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 9, 2024 | finance.yahoo.com

Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 7, 2024 | markets.businessinsider.com

Buy Rating Reiterated for Werewolf Therapeutics Amid Promising INDUKINE Platform Developments

March 7, 2024 | investorplace.com

HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023

March 7, 2024 | benzinga.com

Recap: Werewolf Therapeutics Q4 Earnings

March 7, 2024 | finanznachrichten.de

Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 7, 2024 | globenewswire.com

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 6, 2024 | finance.yahoo.com

HOWL Mar 2024 2.500 put

March 6, 2024 | globenewswire.com

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

March 5, 2024 | globenewswire.com

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

February 27, 2024 | finance.yahoo.com

Werewolf Therapeutics, Inc. (HOWL)

February 21, 2024 | benzinga.com

Werewolf Therapeutics Stock (NASDAQ:HOWL), Short Interest Report

February 20, 2024 | yahoo.com

Do wolf reintroduction programs restore ecosystems? It's not that simple, researchers say

February 20, 2024 | yahoo.com

Cool Video Captures Rare Sight of Wolf Pack Trekking Through Deep Snow in China

February 12, 2024 | msn.com

Wolves howl in different accents

February 10, 2024 | msn.com

Werewolf Therapeutics Expands Offering with $25M Stock Sale

February 8, 2024 | yahoo.com

Watch mesmerizing footage of gray wolf running in the snow captured by Colorado rancher

January 24, 2024 | news.yahoo.com

The Wolf Moon will howl at five planets above Boise this week. Here’s how to view them all

January 19, 2024 | msn.com

Howl review - If you go into the woods today

See More Headlines

Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:HOWL
CUSIP: N/A
CIK: 1785530
Web: werewolftx.com
Phone: 617-952-0555
Fax: N/A
Employees: 47
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.50
High Stock Price Target: $15.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +94.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,370,000.00
Net Margins: -187.37%
Pretax Margin: -187.37%
Return on Equity: -32.25%
Return on Assets: -20.43%

Debt

Debt-to-Equity Ratio: 0.29
Current Ratio: 7.14
Quick Ratio: 7.14

Sales & Book Value

Annual Sales: $19.94 million
Price / Sales: 12.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.08 per share
Price / Book: 1.92

Miscellaneous

Outstanding Shares: 43,350,000
Free Float: 32,033,000
Market Cap: $255.77 million
Optionable: Optionable
Beta: 0.70

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Daniel J. Hicklin Ph.D. (Age 60)
Founder, CEO, President, Secretary & Director
Comp: $817.31k
Dr. Cynthia Seidel-Dugan Ph.D. (Age 65)
Chief Scientific Officer
Comp: $600.35k
Dr. Randi Isaacs M.D. (Age 68)
Chief Medical Officer
Comp: $637.15k
Mr. Timothy W. Trost CPA (Age 66)
CFO, Treasurer & Assistant Secretary
Comp: $511.88k
Dr. Chulani Karunatilake Ph.D. (Age 65)
Chief Technology Officer
Comp: $343.43k
Ms. Ellen A. Lubman M.B.A. (Age 47)
Chief Business Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

HOWL Stock Analysis - Frequently Asked Questions

Should I buy or sell Werewolf Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOWL shares.
View HOWL analyst ratings or view top-rated stocks.
What is Werewolf Therapeutics' stock price target for 2024?: 2 brokerages have issued 12-month target prices for Werewolf Therapeutics' shares. Their HOWL share price targets range from $9.00 to $15.00. On average, they predict the company's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 94.9% from the stock's current price.
View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts.
How have HOWL shares performed in 2024?: Werewolf Therapeutics' stock was trading at $3.86 at the beginning of 2024. Since then, HOWL shares have increased by 52.8% and is now trading at $5.90.
View the best growth stocks for 2024 here.
Are investors shorting Werewolf Therapeutics?: Werewolf Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 472,000 shares, an increase of 9.3% from the March 15th total of 432,000 shares. Based on an average trading volume of 240,200 shares, the short-interest ratio is currently 2.0 days. Currently, 1.6% of the shares of the stock are sold short.
View Werewolf Therapeutics' Short Interest.
When is Werewolf Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HOWL earnings forecast.

How were Werewolf Therapeutics' earnings last quarter?: Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings results on Thursday, March, 7th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.10. The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.75 million. Werewolf Therapeutics had a negative trailing twelve-month return on equity of 32.25% and a negative net margin of 187.37%.
When did Werewolf Therapeutics IPO?: Werewolf Therapeutics (HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
Who are Werewolf Therapeutics' major shareholders?: Werewolf Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Denali Advisors LLC (0.06%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends.
How do I buy shares of Werewolf Therapeutics?: Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HOWL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial